Mundipharma has welcomed
the PBS approval of its new
Flutiform combination inhaler,
which for the first time brings
together fluticasone propionate
with eformoterol.
The combination of an inhaled
corticosteroid (ICS) with a LABA
(long-acting beta-adrenoceptor
agonist) is claimed to “provide
asthma sufferers with rapid onset
of bronchodilation and sustained
improvements in lung function”.
The Flutiform inhaler comes as
an aerosol delivered by a metered
dose inhaler, with an easy-to-read
patient-facing dose counter.
Associate Professor Greg King of
the Woolcock Institute of Medical
Research said Flutiform “is effective
in reaching all goals of asthma
management as it abolishes the
symptoms, improves lung function
and vastly reduces the risk of
attack”.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Feb 14
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.